MedPath

江苏诚康药业有限公司

Ownership
-
Established
2007-08-08
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

7

NMPA:7

Drug Approvals

Bortezomib for Injection

Product Name
注射用硼替佐米
Approval Number
国药准字H20258062
Approval Date
Apr 9, 2025
NMPA

Glucosamine Sulfate Capsules

Product Name
硫酸氨基葡萄糖胶囊
Approval Number
国药准字H20253379
Approval Date
Feb 11, 2025
NMPA

Abiraterone Acetate Tablets

Product Name
醋酸阿比特龙片
Approval Number
国药准字H20244085
Approval Date
Jun 18, 2024
NMPA

Capecitabine Tablets

Product Name
卡培他滨片
Approval Number
国药准字H20243937
Approval Date
Jun 4, 2024
NMPA

Bortezomib for Injection

Product Name
注射用硼替佐米
Approval Number
国药准字H20234692
Approval Date
Dec 26, 2023
NMPA

Pemetrexed Disodium for Injection

Product Name
注射用培美曲塞二钠
Approval Number
国药准字H20233547
Approval Date
May 12, 2023
NMPA

Pemetrexed Disodium for Injection

Product Name
注射用培美曲塞二钠
Approval Number
国药准字H20233548
Approval Date
May 12, 2023
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.